Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Liabilities (2019 - 2021)

Keros Therapeutics (KROS) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $16000.0 as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Other Non-Current Liabilities fell 79.22% year-over-year to $16000.0, compared with a TTM value of $16000.0 through Sep 2021, down 79.22%, and an annual FY2020 reading of $62000.0, down 47.9% over the prior year.
  • Other Non-Current Liabilities was $16000.0 for Q3 2021 at Keros Therapeutics, down from $32000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $119000.0 in Q4 2019 and bottomed at $16000.0 in Q3 2021.
  • Average Other Non-Current Liabilities over 3 years is $68500.0, with a median of $69500.0 recorded in 2020.
  • The sharpest move saw Other Non-Current Liabilities crashed 47.9% in 2020, then tumbled 79.22% in 2021.
  • Year by year, Other Non-Current Liabilities stood at $119000.0 in 2019, then tumbled by 47.9% to $62000.0 in 2020, then tumbled by 74.19% to $16000.0 in 2021.
  • Business Quant data shows Other Non-Current Liabilities for KROS at $16000.0 in Q3 2021, $32000.0 in Q2 2021, and $47000.0 in Q1 2021.